Quest Diagnostics Incorporated $DGX Stock: Robeco Institutional Asset Management B.V. Increases Position

Robeco Institutional Asset Management B.V. boosted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 8.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 122,316 shares of the medical research company’s stock after purchasing an additional 9,770 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Quest Diagnostics were worth $31,198,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DGX. Key Financial Inc raised its holdings in shares of Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after acquiring an additional 121 shares during the period. Ancora Advisors LLC acquired a new position in shares of Quest Diagnostics during the 2nd quarter valued at about $29,000. Frazier Financial Advisors LLC boosted its position in shares of Quest Diagnostics by 492.9% during the 1st quarter. Frazier Financial Advisors LLC now owns 166 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 138 shares during the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of Quest Diagnostics during the 2nd quarter valued at about $45,000. Finally, Dunhill Financial LLC purchased a new stake in shares of Quest Diagnostics in the second quarter valued at about $46,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Quest reported third-quarter revenue of $3.10 billion, up 10% year over year, while adjusted diluted EPS reached $3.00 versus the $2.87 analyst consensus. Reported diluted EPS was $2.78, up 28.7% from the prior year. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Quest raised its 2026 outlook. The company now expects revenue of $12.065 billion to $12.105 billion, reported EPS of $10.21 to $10.31, and adjusted EPS of $11.25 to $11.35. Management cited strong testing demand, volume growth and margin gains. DGX Q3 Earnings and Guidance
• Positive Sentiment: Underlying demand trends were encouraging. Organic requisition volume rose 14.4% in the quarter, and consumer health revenue is expected to grow by more than 30% in 2026, supporting Quest’s longer-term growth strategy. Quest Diagnostics Long-Term Investor Takeaways
• Neutral Sentiment: The market response was mixed. Although the earnings and revenue beats were constructive, some coverage characterized the quarter as merely “good enough,” suggesting that elevated valuation and already-high expectations limited the upside reaction.
• Negative Sentiment: Quest is investigating unauthorized access to its Quanum LSM system. The cybersecurity incident introduces potential operational, remediation, legal and reputational risks, although the company’s ultimate impact assessment was not yet clear. Quest Diagnostics Quanum System Breach

Quest Diagnostics Stock Performance

NYSE DGX opened at $244.90 on Friday. The stock has a market cap of $27.03 billion, a PE ratio of 22.46, a P/E/G ratio of 2.16 and a beta of 0.54. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72. Quest Diagnostics Incorporated has a twelve month low of $171.18 and a twelve month high of $248.84. The stock has a fifty day simple moving average of $237.53 and a 200-day simple moving average of $216.64.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, October 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.87 by $0.13. The firm had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.05 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%. The company’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period last year, the company earned $2.60 EPS. Equities analysts anticipate that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 21st. Investors of record on Tuesday, October 6th were issued a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date was Tuesday, October 6th. Quest Diagnostics’s payout ratio is currently 36.52%.

Insider Activity at Quest Diagnostics

In related news, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the completion of the transaction, the chief executive officer directly owned 122,423 shares in the company, valued at $29,714,510.56. This trade represents a 7.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael E. Prevoznik sold 22,677 shares of Quest Diagnostics stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $243.11, for a total value of $5,513,005.47. Following the completion of the transaction, the senior vice president directly owned 37,557 shares of the company’s stock, valued at approximately $9,130,482.27. This represents a 37.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 34,277 shares of company stock worth $8,316,493. 0.88% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Jefferies Financial Group restated a “buy” rating and set a $245.00 price objective on shares of Quest Diagnostics in a research report on Thursday, July 23rd. Robert W. Baird lifted their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Argus set a $260.00 target price on shares of Quest Diagnostics in a report on Wednesday, July 29th. Barclays increased their price target on shares of Quest Diagnostics from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, UBS Group reissued a “neutral” rating and issued a $250.00 price target on shares of Quest Diagnostics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $243.64.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.